Vaccine maker Adimmune Corp (國光生技) yesterday signed a new contract with Protein Sciences Corp, a subsidiary of Sanofi SA, to continue providing quadrivalent flu vaccine Flublok from 2022 to 2027 in a move to deepen their partnership.
Orders from US-based Protein Science have expanded at a double-digit percentage over the past three years, but Adimmune declined to reveal how many doses of Flublok it is to supply from 2022 to 2027, saying only that the number of orders would be higher than previously.
Adimmune manufactures and packages Flublok at its factory in Taichung’s Tanzi District (潭子).
“The new contract not only grants a source of stable revenue, it also recognizes the quality of manufacturing,” Adimmune said.
Demand for Flublok is expected to rise, as it is the only flu vaccine made without using eggs, minimizing the risk of vaccine resistance as viruses mutate, it said.
Flublok has been marketed in the US since 2017, Adimmune said.
To cope with rising orders, the firm plans to set up a new plant in Taichung to expand its production capacity for flu vaccines, tetanus vaccines and cell-culture products, it said.
The company’s board of directors is to consider the planned investment later this month and the construction of the new plant is likely to be completed by the end of 2022, it said.
Adimmune last month posted record-high revenue of NT$274 million (US$9.13 million) thanks to a payment from the Centers for Disease Control.
The company supplies quadrivalent flu vaccines to the centers for use in its flu vaccination programs. Adimmune finished delivering 4.1 million doses of quadrivalent flu vaccine to the agency on Jan. 2, it said.
Total revenue for last year was NT$1.29 billion, up 58 percent year-on-year.
The company is upbeat about its sales of flu vaccines in Thailand after it gained marketing approval from the nation’s regulator last year, while a phase III clinical trial of its quadrivalent flu vaccine in China is expected to be completed this year, it said.
Separately, TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) on Thursday posted revenue of NT$20 million for last year, down 29.75 percent year-on-year due to a high comparison base.
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) is expected to share his views about the artificial intelligence (AI) industry’s prospects during his speech at the company’s 37th anniversary ceremony, as AI servers have become a new growth engine for the equipment manufacturing service provider. Lam’s speech is much anticipated, as Quanta has risen as one of the world’s major AI server suppliers. The company reported a 30 percent year-on-year growth in consolidated revenue to NT$1.41 trillion (US$43.35 billion) last year, thanks to fast-growing demand for servers, especially those with AI capabilities. The company told investors in November last year that
Intel Corp has named Tasha Chuang (莊蓓瑜) to lead Intel Taiwan in a bid to reinforce relations between the company and its Taiwanese partners. The appointment of Chuang as general manager for Intel Taiwan takes effect on Thursday, the firm said in a statement yesterday. Chuang is to lead her team in Taiwan to pursue product development and sales growth in an effort to reinforce the company’s ties with its partners and clients, Intel said. Chuang was previously in charge of managing Intel’s ties with leading Taiwanese PC brand Asustek Computer Inc (華碩), which included helping Asustek strengthen its global businesses, the company
United Microelectronics Corp (UMC, 聯電) forecast that its wafer shipments this quarter would grow up to 7 percent sequentially and the factory utilization rate would rise to 75 percent, indicating that customers did not alter their ordering behavior due to the US President Donald Trump’s capricious US tariff policies. However, the uncertainty about US tariffs has weighed on the chipmaker’s business visibility for the second half of this year, UMC chief financial officer Liu Chi-tung (劉啟東) said at an online earnings conference yesterday. “Although the escalating trade tensions and global tariff policies have increased uncertainty in the semiconductor industry, we have not
Taiwanese suppliers to Taiwan Semiconductor Manufacturing Co. (TSMC, 台積電) are expected to follow the contract chipmaker’s step to invest in the US, but their relocation may be seven to eight years away, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. When asked by opposition Chinese Nationalist Party (KMT) Legislator Niu Hsu-ting (牛煦庭) in the legislature about growing concerns that TSMC’s huge investments in the US will prompt its suppliers to follow suit, Kuo said based on the chipmaker’s current limited production volume, it is unlikely to lead its supply chain to go there for now. “Unless TSMC completes its planned six
RSS